Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus

Launched by SECOND AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · May 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying the use of lacosamide, a medication given through an IV, to quickly stop a serious condition called status epilepticus (SE), which involves prolonged seizures. SE can be life-threatening if not treated promptly, and this trial aims to find out if lacosamide is an effective and safe option for individuals experiencing this condition. The researchers hope that by using lacosamide, they can reduce the duration of seizures and improve outcomes for patients.

To be eligible for the trial, participants must be between 4 and 60 years old and have experienced specific types of seizures that meet the diagnostic criteria for status epilepticus. This means they either have seizures lasting longer than 5 minutes or have multiple seizures without regaining consciousness in between. Individuals with unstable vital signs or certain heart conditions will not be eligible to participate. If you or someone you know is struggling with prolonged seizures, this trial offers a chance to explore a new treatment option while contributing to important research in epilepsy care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age 4-60 years old, gender is not limited;
• 2. Status epilepticus meets the 2015 diagnostic criteria of the International League Against Epilepsy, i.e., a state of persistent seizures that may cause long-term impairment and manifests itself as:
• • (1) Tonic-clonic seizures or convulsive seizures, lasting \> 5min; (2) Between 2 or more seizures, consciousness is not restored; (3) Focal seizures with impaired consciousness, lasting \>10min; (4) absence seizures, lasting \>15min; 3. Informed consent of the patient and signed a written consent form.
• Exclusion Criteria:
• • 1. Unstable vital signs;
• • 2. Electrocardiogram showing atrial flutter, atrial fibrillation, second-degree, third-degree atrioventricular block;
• • 3. History of allergy to the drugs used this time;
• • 4. Participants have a known history of past or present illness of non-epileptic seizures, and current seizures cannot be judged as status epilepticus based on symptomatology and/or electroencephalogram;
• • 5. Other patients who are considered by the investigator to be unsuitable to participate in the study;
• • 6. Incomplete clinical data or follow-up information